Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA | RA CAPITAL MANAGEMENT L.P. | 18,670,089 9.990% | -20,779 (-0.11%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Tenaya Therapeutics, Inc. TNYA | RA CAPITAL MANAGEMENT L.P. | 6,948,236 9.990% | 519,753 (+8.09%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Vaxcyte, Inc. PCVX | RA CAPITAL MANAGEMENT L.P. | 9,685,079 9.990% | 1,531,520 (+18.78%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | Verona Pharma plc VRNA | RA CAPITAL MANAGEMENT L.P. | 7,503,976 9.990% | -188,014 (-2.44%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Harpoon Therapeutics, Inc. HARP | RA CAPITAL MANAGEMENT L.P. | 1,712,792 9.990% | 11,222 (+0.66%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | Celcuity Inc. CELC | RA CAPITAL MANAGEMENT L.P. | 1,286,960 5.000% | -962,461 (-42.79%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Apogee Therapeutics, Inc. APGE | RA CAPITAL MANAGEMENT L.P. | 1,977,901 5.300% | 1,977,901 (New Position) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | RA CAPITAL MANAGEMENT L.P. | 5,330,412 9.000% | -185,655 (-3.37%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | RA CAPITAL MANAGEMENT L.P. | 3,083,558 9.990% | 8 (+0.00%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2024-02-14 | 13G | NewAmsterdam Pharma Company N.V. NAMS | RA CAPITAL MANAGEMENT L.P. | 8,197,333 9.900% | -1,136,000 (-12.17%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | HilleVax, Inc. HLVX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -1,760,019 (Position Closed) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | Cogent Biosciences, Inc. COGT | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -5,999,481 (Position Closed) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -4,398,453 (Position Closed) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | NanoString Technologies, Inc. NSTGQ | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -2,577,373 (Position Closed) | Filing History |
| 2024-02-13 4:16 pm Purchase | 2024-02-09 | 13D | PepGen Inc. PEPG | RA CAPITAL MANAGEMENT L.P. | 10,695,135 34.100% | 2,563,183 (+31.52%) | Filing History |
| 2024-02-12 4:49 pm Purchase | 2024-02-12 | 13D | Mineralys Therapeutics, Inc. MLYS | RA CAPITAL MANAGEMENT L.P. | 4,949,307 9.990% | 4,949,307 (New Position) | Filing History |
| 2024-02-12 4:18 pm Purchase | 2024-02-02 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | RA CAPITAL MANAGEMENT L.P. | 430,182 4.100% | 430,182 (New Position) | Filing History |
| 2024-02-12 4:17 pm Purchase | 2024-02-01 | 13G | Astria Therapeutics, Inc. ATXS | RA CAPITAL MANAGEMENT L.P. | 4,413,150 8.100% | 4,413,150 (New Position) | Filing History |
| 2024-02-06 4:40 pm Purchase | 2024-02-06 | 13D | Tyra Biosciences, Inc. TYRA | RA CAPITAL MANAGEMENT L.P. | 10,475,489 19.990% | 3,239,035 (+44.76%) | Filing History |
| 2024-02-05 4:30 pm Purchase | 2024-01-25 | 13G | Adicet Bio, Inc. ACET | RA CAPITAL MANAGEMENT L.P. | 7,696,949 9.990% | 7,696,949 (New Position) | Filing History |